Novel 1,4,5,6-tetrahydrocyclopenta[d]imidazole-5-carboxamide-based JNK3 inhibitors: Design, synthesis, molecular docking, and therapeutic potential in neurodegenerative diseases-Reference-Cited by-同舟云学术

Novel 1,4,5,6-tetrahydrocyclopenta[d]imidazole-5-carboxamide-based JNK3 inhibitors: Design, synthesis, molecular docking, and therapeutic potential in neurodegenerative diseases

Published:2023-01 Issue: Volume:245 Page:114917
ISSN:0223-5234
Container-title:European Journal of Medicinal Chemistry
language:en
Short-container-title:European Journal of Medicinal Chemistry

Author:

Jun Joonhong,Baek Jihyun,Kang Dahyun,Moon Hyungwoo,Kim Hyejin,Cho Hyunwook,Hah Jung-Mi^ORCID

Publisher

Elsevier BV

Subject

Organic Chemistry,Drug Discovery,Pharmacology,General Medicine

Reference26 articles.

1. Donepezil for dementia due to Alzheimer's disease;Birks;Cochrane Database Syst. Rev.,2018

2. Rivastigmine for Alzheimer's disease;Birks;Cochrane Database Syst. Rev.,2015

3. Benefits and harms of prescription drugs and supplements for treatment of clinical Alzheimer-type dementia;Fink;Ann. Intern. Med.,2020

4. Targeting JNK for therapeutic benefit: from junk to gold;Manning;Nat. Rev. Drug Discov.,2003

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Update on JNK inhibitor patents: 2015 to present;Expert Opinion on Therapeutic Patents;2024-09-08

2. Recent Molecular Targets and Their Ligands for the Treatment of Alzheimer Disease;Current Topics in Medicinal Chemistry;2024-08-20

3. Special Issue “Alzheimer’s Disease—115 Years after Its Discovery”;Biomedicines;2024-02-21

4. Novel Tryptanthrin Derivatives with Selectivity as c–Jun N–Terminal Kinase (JNK) 3 Inhibitors;Molecules;2023-06-16

5. A patent review of MAPK inhibitors (2018 – present);Expert Opinion on Therapeutic Patents;2023-06-03